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A catalytic asymmetric synthesis of (+)-aza-galacto-fagomine (AGF) – the most promising
compound for the pharmacological chaperone therapy of Krabbe disease – was accomplished in 
six steps, in 14% overall yield. The synthesis hinges on the combination of organocatalyzed 
aldolization and reductive hydrazination. 
2009 Elsevier Ltd. All rights reserved.
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1. Introduction 
Sugar processing enzymes play an important role, in both 
homeostasis and pathological states. Their selective inhibition 
could provide a basis for the treatment of various diseases, such 
as diabetes, cancer, obesity, and viral (including HIV) 
infections.1 Malfunction of lysosomal glycosphingolipid (GSL) 
hydrolases that results in the accumulation of substrates in 
lysosomes, is the cause of a particular class of diseases known 
under the collective name “lysosomal storage disorders”.2 On the 
contrary, Krabbe disease, which is also a consequence of the 
deficiency of lysosomal β-galactocerebrosidase (GALC), does 
not induce glycolipid precipitation, but leads to progressive 
demyelination of the white mass in the central nervous system, as 
well as in peripheral nerves, and neurodegeneration, usually with 
a fatal outcome.3 The presumed agent for this destructive process 
is psychosine, a cytotoxic galactosphingolipid which induces a 
cascade of events leading to cell death.4 The enzyme replacement 
therapy for Krabbe disease is hampered by the fact that GALC 
does not cross the blood-brain barrier. In a number of cases, the 
disease is not caused by the complete absence of GALC, but 
rather by its structural modification, i. e. misfolding. The mutated 
enzyme is not only less efficient, but it cannot leave 
endoplasmatic reticulum. In such cases, a complex between a 
small molecule and the protein could stabilize the correctly 
folded enzyme, thus allowing it to reach lysosome and effect 
there its glycolytic activity. This effect, known as the active site-
specific chaperone effect, provides a basis for the so called 
pharmacological chaperone therapy (PCT): interestingly (and, 
maybe, counterintuitively), at subinhibitory concentrations 
glycosylase inhibitors act as enzyme-rectifying agents. Restoring 
10% of the enzyme activity would be enough to prevent the 
disease. Iminosugars are known to exert strong, yet selective 
inhibitory activity on sugar-processing enzymes. 1-
Deoxygalacto-nojirimycin (DGJ) was shown to enhance α-
galactosidase A activity in patients with Fabry disease.5 Quite 
recently, a similar approach was proposed for the treatment of 
Krabbe disease.6 In a detailed study, a series of azasugars were 
synthesized and tested for their potential as PCT agents. The 
most active among them was aza-galacto-fagomine (AGF). This 
compound was prepared in 16 steps from the commercially 
available 2,3-O-isopropylidene-D-ribofuranose. Chemoenzymatic 
synthesis of AGF was also described (8 steps, 4% overall yield).7 
Further studies of AGF would require an efficient method of 
preparation. Several syntheses of diastereoisomeric azafagomine 
and the derivatives thereof were reported;8 however, the results 
of these studies are not directly applicable to the synthesis of 
AGF. Herein we describe an enantioselective synthesis of AGF 
that may provide a ready access to this compound. 
2. Results and discussion 
For some time, we have explored a tactical combination of 
organocatalyzed aldolization with reductive amination, for the 
efficient construction of polyhydroxylated alkaloids 
(iminosugars). In this way, optically pure members of 
pyrrolidine, piperidine,9 pyrrolizidine10 and indolizidine11 series 
were prepared. We envisaged that a similar approach could be 
applied to the synthesis of AGF, as outlined in retrosynthetic 
format (Scheme 1). The piperazine ring in 1 could be formed by 
“reductive hydrazination” – an analogy of reductive amination 
applied to hydrazino ketone 2 (whereas intermolecular reductive 
hydrazinations have been reported recently, we are aware of only 
a single example of the intramolecular reaction in the literature, 
so far).12 Compound 2 could be further disconnected by an anti- 
 
Scheme 1 
selective aldol transform into dihydroxyacetone and a properly 
protected hydrazino-acetaldehyde 3. 
Previously, others13 and our group9,10,11 have shown dioxanone 
414 to be a convenient synthetic equivalent of a dihydroxyacetone 
enolate in proline-catalyzed enantioselective aldol additions.15 As 
the acceptor component we chose hydrazinoaldehyde 7, whose 
three-step preparation from the commercially available 
hydrazinoethanol (5) was described earlier (Scheme 2).16 It is of 
note that the oxidation step (i. e. 6 → 7) must be performed with 
freshly prepared Dess-Martin periodinane17 (DMP); the use of 
commercial DMP gives rise to impurities in aldehyde 7 that are 
difficult to remove and which affect the optical rotation of the 
intermediates and the final product. The key aldol reaction was 
performed in aqueous DMSO,18 at 4 °C, to afford the aldol 
adduct 8 as a single diastereoisomer (98% ee, determined by 
chiral HPLC, see Supplementary material), in 53% yield 
(comparable results were obtained in DMF as a solvent: 50% 
yield). Catalytic hydrogenation of aldol 8 in pure ethanol resulted 
in the removal of the Cbz protecting group (55%); subsequent 
treatment with NaCNBH3 in the presence of AcOH then gave the 
cyclic product of reductive hydrazination (9; 35%). However, we 
found that these two operations could be better accomplished as a 
one-pot procedure, by performing the catalytic hydrogenation of 
8 in methanol/AcOH (40% yield for the deprotection/cyclization 
tandem). Interestingly, palladium catalyst should be added in 
three portions, as this protocol gives cyclic product 9 of superior 
purity; addition of Pd/C in a single portion results in side 
reactions and contamination of product with impurities. 
Treatment of compound 9 with methanolic HCl effected 
Scheme 2 
deprotection and provided the target compound – AGF (1; 
97%) whose physical properties are in agreement with the 
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literature data.6,7 The three-step conversion of aldol 8 into AGF 
(1) could be effected as a one-pot operation, in 60% yield; 
however, although no visible impurities could have been 
observed in the NMR spectra, the values for optical rotation were 
low, indicating the presence of trace impurities with strong 
levorotatory power. Thus, for the AGF to be analytically pure, 
compound 9 should be purified prior to deprotection. 
3. Conclusions 
To summarize, the catalytic asymmetric synthesis of (+)-aza-
galacto-fagomine (AGF, 1) was accomplished in 6 steps from the 
commercially available alcohol 5, in 14% overall yield, which 
makes this compound readily accessible for further medical 
research. 
4. Experimental section 
4.1. General experimental 
All chromatographic separations were performed on silica gel, 
10–18, 60 Å (dry-flash), 100–200, 60Å (column 
chromatography), ICN Biomedicals, 60 (0.063-0.200 mm) 
(column chromatography), and ion exchange column 
chromatography (acidic resin DOWEX 50WX8-100). Standard 
techniques were used for the purification of reagents and 
solvents.19 Petroleum ether (PE) refers to the fraction boiling at 
70–72 °C. 1H NMR spectra were recorded at 500 MHz, 13C NMR 
at 126 MHz. Chemical shifts are expressed in ppm (δ) using 
TMS as the internal standard. IR spectra were recorded on a FT 
instrument, and are expressed in cm–1. Mass spectra were 
obtained on TOF LC/MS instrument. Melting points are 
uncorrected.  
 
2-Benzyl 1-tert-butyl 1-(2-hydroxyethyl)hydrazine-1,2-
dicarboxylate (6)16 
A solution of (Boc)2O  (2.87 g, 13.15 mmol) in dry ethanol 
(8.0 mL) was added dropwise to a cold (0 °C) solution of N-2-
hydroxyethylhydrazine 5 (1.00 g, 13.14 mmol) in dry ethanol 
(10.0 mL). After 30 min, cooling bath was removed and the 
reaction mixture was stirred for 24 h at room temperature. The 
solvent was removed under reduced pressure and the residue was 
further used without purification. 
A solution of the crude product from the previous experiment 
(2.30 g, 13.05 mmol) in CH2Cl2 (13.6 mL) was added to a 
solution of NaOH (0.57 g, 14.25 mmol) in water (13.6 mL), at 0 
°C, followed by a dropwise addition of benzyl chloroformate 
(1.86 mL, 2.23 g, 13.07 mmol). After 10 min, cooling bath was 
removed and the reaction mixture was stirred for 24 h at room 
temperature. The organic layer was washed with water and  20% 
citric acid aq. solution, dried over anh. MgSO4, filtered and 
concentrated under reduced pressure. Purification of the residue 
by dry-flash chromatography (SiO2; eluent: petroleum 
ether/EtOAc = 8/2) afforded the title alcohol 6 (3.26 g, 80 %) as 
a white solid. mp 58-59 °C; 1H NMR (500 MHz, DMSO-d6, 65 
°C):20 δH 9.21 (bs, 1H), 7.40-7.30 (m, 5H), 5.11 (s, 2H), 4.29 (t, J 
5.6 Hz, 1H), 3.50 (q, J 6.3 Hz, 2H), 3.40 (bs, 2H), 1.37 (s, 9H); 
13C NMR (126 MHz, DMSO-d6, 65 °C): δC 155.8 (C), 154.5 (C), 
136.3 (C), 128.0 (CH), 127.6 (CH), 127.4 (CH), 79.8 (C), 65.8 
(CH2), 57.9 (CH2), 51.7 (CH2), 27.6 (3 × CH3);  IR (ATR) vmax 
3362, 3198, 3009, 2980, 2886, 1716, 1422, 1364, 1288, 1138, 
1061, 737 cm-1; HRMS (ESI) for C15H22N2NaO5 [M+Na]+ 
calculated: 333.1421; found: 333.1422. 
 
2-Benzyl 1-tert-butyl 1-(2-oxoethyl)hydrazine-1,2-
dicarboxylate (7)16 
Freshly prepared Dess-Martin’s periodinane (3.00 g, 7.07 
mmol) was added to a solution of alcohol 6 (0.95 g, 3.06 mmol) 
in water-saturated dichloromethane (28.0 mL) and the reaction 
mixture was stirred at room temperature for 1 h. The reaction 
mixture was diluted with dichloromethane, washed with 10% 
Na2S2O3 (2 × 50 mL), sat. aq. NaHCO3 (2 × 50 mL) and brine 
(50 mL), dried over anh. MgSO4, filtered and concentrated under 
reduced pressure. Purification of the residue by dry-flash 
chromatography (SiO2; eluent: petroleum ether/EtOAc = 7/3) 
afforded aldehyde 7 (0.80 g, 85 %) as a pale yellow viscous oil. 
1H NMR (500 MHz, CDCl3; at room temperature the compound 
exists as a mixture of rotamers21): δH 9.66 (bs, 1H), 7.35 (s, 5H), 
7.02 (bs, NH, 1H; minor rotamer) and 6.91 (bs, NH, 1H; major 
rotamer), 5.16 (s, 2H), 4.33 (bs, 2H; major rotamer),  and 4.24 
(bs, 2H, minor rotamer), 1.45 (s, 9H; minor rotamer) and 1.39 (s,  
9H; major rotamer); 13C NMR (126 MHz, CDCl3): δC 197.9 
(CH), 156.2 and 155.7 (C), 155.0 and 154.6 (C), 135.5 and 135.4 
(C), 128.6 and 128.5 (CH), 128.4 and 128.3 (CH), 128.2 and 
128.2 (CH), 83.1 and 82.5 (C), 67.8 and 67.7 (CH2), 61.2 and 
59.5 (CH2), 28.0 and 27.9 (3 × CH3);  IR (ATR) vmax 3302, 2979, 
2935, 1714, 1501, 1371, 1259, 1154, 1067, 756 cm-1; HRMS 
(ESI) for C15H20N2NaO5 [M+Na]+ calculated: 331.1264; found: 
331.1270. 
 
2-Benzyl 1-tert-butyl 1-((R)-2-((R)-2,2-dimethyl-5-oxo-1,3-
dioxan-4-yl)-2-hydroxyethyl)hydrazine-1,2-dicarboxylate (8) 
Aldehyde 7 (800 mg, 2.59 mmol) was added to a solution of 
D-proline (90.0 mg, 0.78 mmol, 30 mol %) in DMSO (9.0 mL). 
Next, dioxanone 4 (900 mg, 6.92 mmol) and water (206.0 µL, 
11.44 mmol) were added to the flask and the mixture was 
vigorously stirred for 48 h at 4 °C. The reaction mixture was 
diluted with EtOAc and washed with water (50 mL). The 
aqueous phase was back-extracted with EtOAc (2 × 50 mL). The 
combined organic extract was dried over anh. MgSO4, filtered 
and concentrated under reduced pressure. Purification of the 
crude product by column chromatography (SiO2; eluent: 
petroleum ether/acetone = 8/2) afforded the title aldol 8 (604.0 
mg, 53%) as a pale yellow, viscous oil. [α]D20 +70.0 (c 1.00, 
CHCl3); 1H NMR (500 MHz, DMSO-d6, 65 °C) δH 9.15 (bs, NH, 
1H), 7.38-7.32 (m, 5H), 5.12 (s, 2H), 4.39 (s, 1H), 4.26 (dd, J 
16.7, 1.2 Hz, 1H), 4.06 (td, J 6.5, 3.0 Hz, 1H), 3.93 (d, J 16.7 Hz, 
1H), 3.55 (bs, 2H), 3.15 (bs, OH, 1H), 1.41 (s, 6H), 1.37 (s, 9H); 
13C NMR (126 MHz, DMSO-d6, 65 °C) δC 206.9 (C), 155.7 (C), 
154.5 (C), 136.2 (C), 128.0 (CH), 127.6 (CH), 127.3 (CH), 99.6 
(C), 79.9 (C), 76.2 (CH), 67.5 (CH), 66.5 (CH2), 65.8 (CH2), 51.8 
(CH2), 27.5 (3 × CH3), 24.3 (CH3), 22.8 (CH3); IR (ATR) vmax 
3306, 2984, 2938, 1743, 1714, 1374, 1224, 1158, 1086, 859, 754 
cm
-1; HRMS (ESI) for C21H30KN2O8 [M+K]+ calculated: 
477.1634; found: 477.1635. The optical purity of compound 8 
was determined by chiral HPLC as >98% ee (See the 
Supplementary material for details, page S12). 
 
(4R,4aS,8aR)-tert-Butyl 4-hydroxy-6,6-
dimethyltetrahydro-1H-[1,3]dioxino[5,4-c]pyridazine-2(3H)-
carboxylate (9) 
10% Pd/C (4.4 mg, 0.004 mmol, 7.5 mol %) was added to a 
solution of aldol 8 (23.1 mg, 0.053 mmol) in a solvent mixture 
methanol/acetic acid (3.7 mL, v/v= 7/1), and the reaction mixture 
was stirred at room temperature under a hydrogen atmosphere 
(20 at). After 2 h a second portion of Pd/C (8.8 mg, 0.008 mmol, 
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15 mol %) was added, and after 24 h a third portion of Pd/C 
(4.4 mg, 0.004 mmol, 7.5 mol %) was added. The total time of 
the reaction was 48 h. The mixture was filtered through celite and 
concentrated under reduced pressure. Purification of the residue 
by column chromatography (SiO2; eluent: petroleum 
ether/EtOAc = 1/2) afforded the title compound (9) (6.0 mg, 
40%) as a white solid. mp 180-181 °C; [α]D20 +50.9 (c 1.20, 
MeOH); 1H NMR (500 MHz, DMSO-d6, 65 °C) δH 4.59 (d, J 5.7 
Hz, 1H), 4.23 (d, J 11.4 Hz, 1H), 4.07-4.00 (m, 2H), 3.81 (dd, J 
12.2, 5.2 Hz, 1H), 3.60 (dd, J 12.3, 1.6 Hz, 1H), 3.49-3.42 (m, 
1H), 2.90 (t, J 11.7 Hz, 1H), 2.54-2.50 (m, 1H), 1.41 (s, 3H), 
1.40 (s, 9H), 1.35 (s, 3H); 13C NMR (126 MHz, DMSO-d6, 65 
°C) δC 154.4 (C), 97.9 (C), 78.5 (C), 66.5 (CH), 65.8 (CH), 61.3 
(CH2), 51.3 (CH), 45.0 (CH2), 28.9 (CH3), 27.8 (3 x CH3), 18.5 
(CH3); IR (ATR) vmax 3417, 3250, 2983, 2973, 1695, 1502, 1385, 
1177, 1066, 993, 853 cm-1; HRMS (ESI) for C13H24N2NaO5 
[M+Na]+ calculated: 311.1577; found: 311.1584. 
 
(3R,4S,5R)-3-(hydroxymethyl)piperazine-4,5-diol (aza-
galacto-fagomine) (1) 
A solution of compound 9 (21.0 mg, 0.07 mmol) in a solvent 
mixture methanol/3M HCl (3.6 mL, v/v= 1/1) was stirred at room 
temperature for 24 h. After the volatiles were removed under 
reduced pressure, the residue was purified by ion exchange 
column chromatography (acidic resin DOWEX 50WX8-100) to 
give (+)-aza-galacto-fagomine (AGF, 1) (10.5 mg, 97%) as a 
colorless film. [α]D20 +10.4 (c 1.00, H2O), [lit.7 [α]D20 +11.9 (c 
1.00, H2O)]; [lit.6 [α]D20 +9.0 (c 1.00, H2O)]; 1H NMR (500 MHz, 
D2O) δH 4.02-3.99 (m, 1H), 3.79 (ddd, J 11.0, 5.2, 3.0 Hz, 1H), 
3.64 (d, J 6.3 Hz, 2H), 2.96-2.87 (m, 2H), 2.81 (dd, J 12.6, 11.1 
Hz, 1H); 13C NMR (126 MHz, D2O) δC 64.9 (CH), 63.7 (CH), 
58.1 (CH), 57.6 (CH2), 43.5 (CH2); IR (ATR) vmax 3274, 2932, 
1570, 1413, 1102, 1029, 817, 657 cm-1; HRMS (ESI) for 
C5H13N2O3 [M+H]+ calculated: 149.0921; found: 149.0924. 
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